Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination

שמור ב:

מידע ביבליוגרפי
מחבר ראשי:	Feng Wang (44414) (author)
מחברים אחרים:	Yang Liu (3703639) (author), Wanglong Qiu (710981) (author), Elaine Shum (14955138) (author), Monica Feng (9566474) (author), Dejian Zhao (14955141) (author), Deyou Zheng (12490640) (author), Alain Borczuk (451970) (author), Haiying Cheng (4787832) (author), Balazs Halmos (5171009) (author)
יצא לאור:	2025
נושאים:	Cancer Cancer Biology Tumor Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Signaling Receptors Drug Targets Cell surface receptor drug targets Gene Technologies High-throughput sequencing Lung Cancer Oncogenes & Tumor Suppressors Oncogenes Progression, Invasion & Metastasis Small Molecule Agents Translational Research
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
מאת: Feng Wang (44414)
יצא לאור: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
מאת: Feng Wang (44414)
יצא לאור: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
מאת: Feng Wang (44414)
יצא לאור: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
מאת: Anne-Florence Blandin (15056366)
יצא לאור: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
מאת: Anne-Florence Blandin (15056366)
יצא לאור: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
מאת: Anne-Florence Blandin (15056366)
יצא לאור: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
מאת: Anne-Florence Blandin (15056366)
יצא לאור: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
מאת: Anne-Florence Blandin (15056366)
יצא לאור: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
מאת: Anne-Florence Blandin (15056366)
יצא לאור: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
מאת: Anne-Florence Blandin (15056366)
יצא לאור: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
מאת: Smruthy Sivakumar (15053536)
יצא לאור: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
מאת: Ana Vujovic (15207479)
יצא לאור: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
מאת: Katie E. Hebron (15046889)
יצא לאור: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
מאת: Katie E. Hebron (15046889)
יצא לאור: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
מאת: Katie E. Hebron (15046889)
יצא לאור: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
מאת: Katie E. Hebron (15046889)
יצא לאור: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
מאת: Katie E. Hebron (15046889)
יצא לאור: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
מאת: Katie E. Hebron (15046889)
יצא לאור: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
מאת: Katie E. Hebron (15046889)
יצא לאור: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
מאת: Yuanqing Ma (15052437)
יצא לאור: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
מאת: Srivandana Akshintala (16610490)
יצא לאור: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
מאת: Srivandana Akshintala (16610490)
יצא לאור: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
מאת: Yuncheng Bei (16546095)
יצא לאור: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
מאת: Yuncheng Bei (16546095)
יצא לאור: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
מאת: Yuncheng Bei (16546095)
יצא לאור: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lpc1p65rem52k15ffuirpp956h